Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-002, "Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)"
Notice Number:
NOT-DA-21-010

Key Dates

Release Date:

November 12, 2020

Related Announcements

RFA-MD-21-002 - Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in RFA-MD-21-002, "Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)".

The following text has been added to reflect NIDA's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.279

Part 2. Section I. Funding Opportunity Description

NIDA is interested in the following areas of research involving people who use drugs (PWUD) including key populations e.g., Black/African American gay, bisexual, and men who have sex with men(MSM), Hispanics/Latinos MSM, Transgender Women, Female Sex Workers (FSW), High Risk Heterosexuals of racial ethnic minority groups (HRH) where drug use is a common contributing HIV risk:

Areas of special interest include but are not limited to the following:

  • Testing of interventions in HIV and substance use disorder (SUD) care, and harm reduction service settings in multiple geographic hotspots.
  • Interventions that directly engage sexual and/or injecting partners in ART adherence and HIV risk behavior reduction intervention components.
  • Interventions that include clinician- or clinic-level intervention components to enhance cultural competency and reduce health-care related stigma and discrimination towards HIV positive individuals and PWUD and are HIV positive, racial/ethnic minorities, and/or sexual and gender minorities.
  • Engagement of members of the target high-risk health disparity populations or subgroups including as investigators, advisors, or peer interventionists.
  • Collaboration with diverse local stakeholders in addition to HIV care providers, including other types of healthcare providers including care providers engaged in SUD prevention and care, school systems, justice settings, school-based student or parent associations, community-based organizations, consumer organizations, patient advocacy organizations, and faith-based organizations to enhance intervention relevance, feasibility, and sustainability.
  • Projects that examine cost-effectiveness of intervention implementation and delivery

Part 2. Section II, Award Information

Funds Available and Anticipated Number of Awards

NIDA intends to commit $1M in FY2021 to fund 2 awards.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Minnjuan Flournoy Floyd, PhD
National Institute on Drug Abuse (NIDA)
Telephone:301-827-6474
Email: Minnjuan.flournoyfloyd@nih.gov

Financial/Grants Management Contact(s)
 Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@nida.nih.gov

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Minnjuan Flournoy Floyd, PhD
National Institute on Drug Abuse (NIDA)
Telephone:301-827-6474
Email:Minnjuan.flournoyfloyd@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices